Trial of Botulinum Toxin for Isolated or Essential Head Tremor
NEJM 389:1753-1765, Marques,A.,et al, 2023
Evidence-based guideline update: Treatment of Essential Tremor
Neurol 77:1752-1755, Zesiewicz, T.A.,et al, 2011
Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007
A 75-Year-Old Man With Cognitive Impairment and Gait Changes, Lewy Body Disease
Neurol 69:1183-1189, Lippa,C.F.,et al, 2007
A Double-blind Placebo-controlled Trial of Topiramate Treatment for Essential Tremor
Neurol 59:132-134, Connor,G.S., 2002
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Botulinum Toxin Treatment of Tremors
Neurol 41:1185-1188, Jankovic,J.&Schwartz,K., 1991
Induction of Parkinsonism by Intraventricular Bethanechol in a Patient with Alzheimer's Disease
Neurol 39:1265, Fox,J.H.,et al, 1989
Acute and Chronic Effects of Propranolol and Primidone in Essential Tremor
Neurol 39:1587-1588, Koller,W.C.&Vetere-Overfield,B., 1989
Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons with Dementia
Neurol 105: e213717, Zissimopoulos, J.,et al, 2025
Rabbit Syndrome
Neurol102:e209275, Huynh,T.U., & Beckley, E.H., 2024
Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
A 59-Year-Old Woman Presenting with Diplopia, Dysarthria, Right-sided Weakness, and Encephalopathy
Neurol 97:e859-e864, Manzano, G.S.,et al, 2021
Tardive Diaphragmatic Tremor
Neurol 94:e656, Gupta, H.V., 2020
A 54-year-old woman with Dementia, Myoclonus, and Ataxia
Neurol 89:e7-e12, Ali, F.,et al, 2017
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Serotonin Reuptake Inhibitors and Related Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1212, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Lithium
Adams & Victors Principles of Neurology Chp 43, pg 1212, Ropper, A.H.,et al, 2014
Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
Reversible Parkinsonism and Ataxia Associated With High-Dose Octreotide
Neurol 70:2345-2346, Espay,A.J., 2008
A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Cetirizine-Induced Dystonic Movements
Neurol 66:143-144, Rajput,A. &Baerg,K., 2006
What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Delusions and Hallucinations in Dementia with Lewy Bodies: Worsening with Memantine
Neurol 65:481-482, Ridha,B.H.,et al, 2005
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Reversible Parkinsonism with Normal B-CIT-SPECT in Patients Exposed to Sodium Valproate
Neurol 62:1435-1437, Easterford,K.,et al, 2004
Atypical Antipsychotic Drugs in the Treatment of Behavioural and Psychological Symptoms of Dementia: Systematic Review
BMJ 329:75-78, Lee,P.E.,et al, 2004
Treatment of Wilson Disease With Ammonium Tetrathiomolybdate, III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy
Arch Neurol 60:379-385, Brewer,G.J.,et al, 2003
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 289:2651-2662,2717, Shumaker,S.A.,et al, 2003
Subacute Meningoencephalitis in a Subset of Patients with AD After AB42 Immunization
Neurol 61:46-54,7, Orgogozo,J.M.,et al, 2003
Dementia with Lewy Bodies
Lancet 362:1689-1690, Wilcock,G.K., 2003